The promise and challenges of RNA-targeted therapeutics in preventive cardiology
- 23 July 2021
- journal article
- editorial
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 43 (7) , 550-552
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemiaEuropean Heart Journal, 2020
- Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL CholesterolNew England Journal of Medicine, 2020
- Lipoprotein(a) Reduction in Persons with Cardiovascular DiseaseNew England Journal of Medicine, 2020
- N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levelsEuropean Heart Journal, 2019
- Advances in lipid-lowering therapy through gene-silencing technologiesNature Reviews Cardiology, 2018
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular DiseaseNew England Journal of Medicine, 2017
- Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus PanelEuropean Heart Journal, 2017
- Genetics of coronary artery disease: discovery, biology and clinical translationNature Reviews Genetics, 2017